3-Carbamoyl-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-pyridinium | 108646-19-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Carbamoyl-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-pyridinium
• 英文别名: 1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide
• CAS: 108646-19-1
• 化学式: C₁₁H₁₅N₂O₅
• 分子量: 255.25
• InChiKey: JLEBZPBDRKPWTD-SDNRWEOFSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-Carbamoyl-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-pyridinium 在 potassium chloride 作用下， 生成 D-arabinofuranose
  参考文献：
  名称：

  Substituent effects on the pH-independent hydrolysis of 2'-substituted nicotinamide arabinosides

  摘要：

  The rates of the pH-independent hydrolysis of a series of 2'-substituted nicotinamide arabinosides have been measured and are used to analyze the direct inductive substituent effect on the stability of oxocarbocationic intermediates.

  DOI：

  10.1021/jo00017a004

文献信息

• [EN] PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE<br/>[FR] PRÉPARATION ET UTILISATION DE BÊTA-D-NICOTINAMIDE RIBOSIDE CRISTALLIN
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2015186068A1

  公开（公告）日：2015-12-10

  Provided herein are crystalline beta-D-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof. The crystalline beta-D-nicotinamide riboside chloride compositions may be used to treat a disease or disorder that would benefit from increased NAD levels including a mitochondrial disease or disorder, insulin resistance, a metabolic syndrome, diabetes, obesity, or for increasing insulin sensitivity in a subject.

  本文提供晶体质的β-D-烟酰胺核苷酸氯化物组合物的制备和使用方法。还提供相关的药物组合物及其使用方法。晶体质的β-D-烟酰胺核苷酸氯化物组合物可用于治疗需要提高NAD水平的疾病或疾病，包括线粒体疾病或疾病，胰岛素抵抗，代谢综合征，糖尿病，肥胖症或用于增加受试者胰岛素敏感性。
• PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE
  申请人：GlaxoSmithKline Intellectual Property (No. 2) Limited

  公开号：EP3149016A1

  公开（公告）日：2017-04-05